ClinicalTrials.gg

Program

cemiplimab

Also written as “Cemiplimab”, “REGN2810” and “REGN2810/chemo/ipi”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Carcinoma, Basal Cell · Squamous Cell Carcinoma of Head and Neck · Neoplasm Metastasis, led by 7 companies.

Furthest: phase 3, since Mar 3, 201742 company-led studies, 18 open or runningNext primary completion: Mar 22, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals3516 open or runningphase 3since Mar 3, 2017Feb 2, 2015Mar 22, 2027phase 3 · NCT06246916
BioNTech20 open or runningphase 2since Apr 21, 2020Apr 21, 2020none ahead
Maia Biotechnology11 open or runningphase 3since Mar 20, 2025Mar 20, 2025Jul 31, 2027phase 3 · NCT06908304
Merck KGaA, Darmstadt, Germany10 open or runningphase 2since May 22, 2023May 22, 2023none ahead
Sanofi10 open or runningphase 2since Jun 19, 2017Jun 19, 2017none ahead
SillaJen10 open or runningphase 2since Sep 19, 2017Sep 19, 2017none ahead
Vyriad11 open or runningphase 2since Feb 25, 2020Feb 25, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 29 studies since Feb 2, 2015.

  1. Sep 23, 2022Phase 2 study in Advanced Non-Small Cell Lung CancerRegeneron Pharmaceuticals · NCT05557591 · 51 enrolled · United States, Georgia, Germany and more
  2. May 22, 2023Merck KGaA, Darmstadt, Germany's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT05882734 · 61 enrolled · United States, Belgium, France and more
  3. Nov 9, 2023Phase 2 study in MelanomaRegeneron Pharmaceuticals · NCT06190951 · 151 enrolled · United States, Australia, Austria and more
  4. Jan 30, 2024Phase 3 study in MelanomaRegeneron Pharmaceuticals · NCT06246916 · 560 planned · United States, Canada
  5. Apr 22, 2024Phase 2 study in Cutaneous Squamous Cell CarcinomaRegeneron Pharmaceuticals · NCT06384820
  6. May 9, 2024Phase 2 study in MelanomaRegeneron Pharmaceuticals · NCT06413680 · 240 planned · United States
  7. Jun 6, 2024Phase 1 study in Carcinoma, Ovarian EpithelialRegeneron Pharmaceuticals · NCT06469281 · 90 planned · United States
  8. Sep 3, 2024Phase 3 study in Skin NeoplasmsRegeneron Pharmaceuticals · NCT06585410 · 369 planned · United States, Australia
  9. Jan 6, 2025Phase 2 study in Squamous Cell Carcinoma of Head and NeckRegeneron Pharmaceuticals · NCT06769698 · 120 planned · United States, Australia, France and more
  10. Feb 24, 2025Phase 2 study in MelanomaRegeneron Pharmaceuticals · NCT06848088 · 28 enrolled · United States, Ireland
  11. Mar 20, 2025Maia Biotechnology's first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to Maia BiotechnologyMaia Biotechnology · NCT06908304 · 300 planned · Poland, Romania, Taiwan and more
  12. Apr 28, 2026Phase 2 study in GliomaRegeneron Pharmaceuticals · NCT07567469 · 120 planned
  13. Sep 1, 2026Phase 2 study in Skin NeoplasmsRegeneron Pharmaceuticals · NCT07808515 · 135 planned
  14. Nov 10, 2026Primary completion moved from 2029-10-10 to 2030-10-09Date moved laterphase 2 · +12 months · NCT06848088

Ahead

  1. Nov 2, 2026Primary completion: phase 2 study in MelanomaRegeneron Pharmaceuticals · NCT06190951
  2. Nov 13, 2026Primary completion: phase 2 study in Advanced Solid TumorsRegeneron Pharmaceuticals · NCT04626635
  3. Mar 22, 2027Primary completion: phase 3 study in MelanomaRegeneron Pharmaceuticals · NCT06246916
  4. Apr 29, 2027Primary completion: phase 1 study in Neoplasm MetastasisRegeneron Pharmaceuticals · NCT05259709

TargetBeta

PDCD1 →read by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 42 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07808515Skin Neoplasms2Not yet recruitingRegeneron PharmaceuticalsNov 13, 2030135
NCT07567469Glioma2Not yet recruitingRegeneron PharmaceuticalsAug 27, 2032120
NCT06908304Carcinoma, Non-Small-Cell Lung · Poland, Romania, Taiwan and more3RecruitingMaia BiotechnologyJul 31, 2027300
NCT06848088Melanoma · United States, Ireland2Active, not recruitingRegeneron PharmaceuticalsOct 9, 203028
NCT06769698Squamous Cell Carcinoma of Head and Neck · United States, Australia, France and more2RecruitingRegeneron PharmaceuticalsJun 4, 2028120
NCT06585410Skin Neoplasms · United States, Australia3RecruitingRegeneron PharmaceuticalsMay 3, 2030369
NCT06469281Carcinoma, Ovarian Epithelial · United States1RecruitingRegeneron PharmaceuticalsMay 27, 203090
NCT06413680Melanoma · United States2RecruitingRegeneron PharmaceuticalsFeb 3, 2030240
NCT06384820Cutaneous Squamous Cell Carcinoma2WithdrawnRegeneron PharmaceuticalsJun 8, 20260
NCT06246916Melanoma · United States, Canada3RecruitingRegeneron PharmaceuticalsMar 22, 2027560
NCT06190951Melanoma · United States, Australia, Austria and more2Active, not recruitingRegeneron PharmaceuticalsNov 2, 2026151
NCT05882734Carcinoma, Non-Small-Cell Lung · United States, Belgium, France and more2CompletedMerck KGaA, Darmstadt, GermanyJul 15, 202661
NCT05557591Advanced Non-Small Cell Lung Cancer · United States, Georgia, Germany and more2Active, not recruitingRegeneron PharmaceuticalsJan 26, 202851
NCT05259709Neoplasm Metastasis · Netherlands1Active, not recruitingRegeneron PharmaceuticalsApr 29, 202722
NCT04626635Advanced Solid Tumors · United States, France, Israel and more2Active, not recruitingRegeneron PharmaceuticalsNov 13, 2026548
NCT04526899Melanoma · United States, Australia, Germany and more2CompletedBioNTechJan 25, 2024184
NCT04382898Prostatic Neoplasms · United States, Germany, Hungary and more2TerminatedBioNTechJan 23, 202475
NCT04373083Hodgkin Disease2WithdrawnRegeneron PharmaceuticalsDec 20, 20220
NCT04291105Melanoma · United States, Brazil2Active, not recruitingVyriadOct 202687
NCT04154943Cutaneous Squamous Cell Carcinoma · United States, Australia, Germany2CompletedRegeneron PharmaceuticalsDec 1, 202179
NCT03969004Cutaneous Squamous Cell Carcinoma · United States, Australia, Belgium and more3Active, not recruitingRegeneron PharmaceuticalsJan 7, 2028415
NCT03916627Carcinoma, Non-Small-Cell Lung · United States2Active, not recruitingRegeneron PharmaceuticalsMar 31, 202565
NCT03889912Carcinoma, Basal Cell · United States, Australia, Netherlands1CompletedRegeneron PharmaceuticalsNov 13, 202597
NCT03690869Central Nervous System Neoplasms · United States2TerminatedRegeneron PharmaceuticalsMay 10, 202357
NCT03580694Carcinoma, Non-Small-Cell Lung · United States1TerminatedRegeneron PharmaceuticalsDec 4, 201917
NCT03564340Ovarian Neoplasms · United States, Australia, Belgium and more2RecruitingRegeneron PharmaceuticalsMay 10, 2027890
NCT03515629Carcinoma, Non-Small-Cell Lung · United States, Italy, Lithuania3TerminatedRegeneron PharmaceuticalsJul 29, 20215
NCT03430063Advanced Non-Small Cell Lung Carcinoma · United States, Belgium, France and more2TerminatedRegeneron PharmaceuticalsOct 27, 202128
NCT03409614Carcinoma, Non-Small-Cell Lung · United States, Austria, China and more3CompletedRegeneron PharmaceuticalsFeb 27, 2025789
NCT03294083Carcinoma, Renal Cell · United States, Australia, South Korea2CompletedSillaJenFeb 16, 202395
NCT03257267Carcinoma, Squamous Cell · United States, Australia, Belgium and more3CompletedRegeneron PharmaceuticalsMar 15, 2021608
NCT03233139Advanced Malignancies · Japan1Active, not recruitingRegeneron PharmaceuticalsSep 30, 2027146
NCT03198130Recurrent Squamous Cell Carcinoma of Head · Korea, Republic of, United Kingdom1CompletedRegeneron PharmaceuticalsJun 27, 201933
NCT03194867Multiple Myeloma · United States, Australia, Brazil and more2CompletedSanofiApr 5, 2023109
NCT03132636Carcinoma, Basal Cell · United States, Austria, Belgium and more2CompletedRegeneron PharmaceuticalsMay 20, 2021138
NCT03088540Carcinoma, Non-Small-Cell Lung · Australia, Belarus, Brazil and more3CompletedRegeneron PharmaceuticalsApr 18, 2025712
NCT03002376Melanoma · Korea, Republic of, Netherlands, Serbia and more1CompletedRegeneron PharmaceuticalsMar 5, 201947
NCT03005782Neoplasms · United States, Australia, Ireland and more1CompletedRegeneron PharmaceuticalsApr 2, 2024333
NCT02760498Advanced Cutaneous Squamous Cell Carcinoma · United States, Australia, Brazil and more2CompletedRegeneron PharmaceuticalsOct 18, 2023432
NCT02651662Recurrence · United States, Austria, Germany and more1CompletedRegeneron PharmaceuticalsApr 29, 2026105
NCT02520245Advanced Malignancies · United States1WithdrawnRegeneron PharmaceuticalsNov 20230
NCT02383212Advanced Cancer · United States, Australia, Spain1CompletedRegeneron PharmaceuticalsNov 18, 2019398

How it is read

Names in the registry

  • “Cemiplimab”, 23 entries
  • “cemiplimab”, 9 entries
  • “REGN2810”, 4 entries
  • “REGN2810/chemo/ipi”, 2 entries
  • “Fianlimab+cemiplimab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.